logo

CNTA

Centessa·NASDAQ
--
--(--)
--
--(--)
1.44 / 10
Underperform

Fundamental analysis of Centessa Pharmaceuticals reveals a score of 1.4/10, signaling significant challenges. Key weaknesses include a high Net profit / Total profit ratio (101.8143, group 2) and a large PB-ROE difference (6.1567, group 4), both associated with lower returns. Although some factors like Inventory turnover ratio (47.8766, group 2) and Interest coverage ratio (15.5059, group 1) show decent efficiency, they are outweighed by negative indicators. Revenue growth is strong (Total operating revenue YoY +78.6242%, group 2; Operating revenue YoY +92.7872, group 2), yet the overall fundamental structure remains unfavorable for value-oriented investors.

Fundamental(1.44)SentimentTechnical

Analysis Checks(6/10)

Revenue-MV
Value-0.26
Score1/3
Weight13.60%
1M Return3.98%
Total operating revenue (YoY growth rate %)
Value78.62
Score3/3
Weight2.54%
1M Return0.88%
Inventory turnover ratio
Value47.88
Score2/3
Weight-3.27%
1M Return-1.23%
Profit-MV
Value0.47
Score2/3
Weight31.58%
1M Return8.99%
PB-ROE
Value6.16
Score0/3
Weight11.24%
1M Return3.36%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.51
Score2/3
Weight-3.41%
1M Return-1.25%
Operating revenue (YoY growth rate %)
Value92.79
Score2/3
Weight0.29%
1M Return0.10%
Asset-MV
Value-0.51
Score0/3
Weight21.34%
1M Return6.58%
Net profit / Total profit (%)
Value101.81
Score1/3
Weight-4.23%
1M Return-1.59%
Cash-MV
Value-0.07
Score2/3
Weight30.32%
1M Return8.80%
Is CNTA fundamentally strong?
  • CNTA scores 1.44/10 on fundamentals and holds a Premium valuation at present. Backed by its -37.37% ROE, 0.00% net margin, -12.98 P/E ratio, 10.44 P/B ratio, and -24.34% earnings growth, these metrics solidify its Underperform investment rating.